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The response to chemotherapy of a variety of human
tumour xenografts
G.G. Steel, V.D. Courtenay & M.J. Peckham
Radiotherapy Research Unit, Institute ofCancer Research, Sutton, Surrey.
Summary The results of a series of projects on the cytotoxic drug response of human tumour xenografts are
compared. All were performed in one laboratory, using conventional CBA mice that were usually immuno-
suppressed by thymectomy, cytosine arabinoside treatment, and whole-body irradiation. Results on human
tumours arising in 9 anatomical sites are included, with the main emphasis on colo-rectal, pancreas, breast,
lung and testis carcinomas, also melanomas. Growth acceleration during successive passage of most of these
tumour types was observed. When therapeutic response was measured by a growth-delay method there were
wide differences in response to chemotherapy. Testicular teratomas and small-cell lung tumours responded
well; breast tumours showed modest response; melanomas, colo-rectal tumours and non-small-cell lung
tumours responded poorly. Studies of clonogenic cell survival were made in 11 xenografted tumour lines.
They confirmed the range of responsiveness and tendency towards individuality of the growth delay data. Cell
survival in most cases was exponentially related to drug dose. This compilation of a large amount of
experimental data supports the belief that human tumour xenografts broadly maintain the level of
chemotherapeutic responsiveness of the source tumours in man.
During the past seven years we have coordinated a
substantial programme of work on human tumour
xenografts in immuno-suppressed mice. Much of the
work was performed by clinical scientists who were
released from clinical work to pursue a 1-2 year
period of laboratory research; their names are listed
below.* Each project concentrated upon a specific
category of human cancer and led to its own
specific conclusions. The purpose of this review is to
bring together the therapeutic results of all these
investigations and to present such general
conclusions as can be drawn at the present time.
These conclusions relate to two main questions:
How satisfactory are human tumour xenografts for
the evaluation of therapeutic response? and, To
what extent do the results correspond with clinical
experience in chemotherapy?
Immuno-suppressed mice
The earliest studies in this series of experiments
were performed using CBA mice that were immuno-
suppressed by 9Gy whole-body radiation followed
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immediately by a bone marrow graft (Kopper &
Steel, 1975; Nowak et al., 1978). The conventional
procedure involved a graft of 5 x 106 nucleated
marrow cells for reconstitution. Attempts to
improve the receptivity of the mice to human
tumour grafts indicated that some improvement was
gained by reducing the size of the marrow graft to
2 x 105 cells and the mice survived equally well.
This procedure was not extensively used, however,
because of the development of a simpler and
probably more effective procedure.
It has been observed (Millar et al., 1978) that a
number of cytotoxic drugs, given to mice a few days
before whole-body radiation, increase the dose of
radiation that can be tolerated. Increased radiation
resistance is found both in the bone marrow and in
the intestinal epithelium (Phelps & Blackett, 1979).
Among the various drugs that produce this effect,
cytosine arabinoside (Ara C) is particularly useful,
since it produces a good degree of protection and is
well tolerated in single doses. The optimum
procedure is to give 200mgkg-1 i.p. 48h before
irradiation. Steel et al., (1978) found that this
allowed mice to tolerate 9Gy whole-body
irradiation without the need of a bone marrow
graft; cell titration tests using cells from a
xenografted human pancreatic carcinoma showed
that mice prepared in this way were more receptive
to grafting than marrow-reconstituted mice or even
than nude mice. This procedure has been standard
in this Department since that time.
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An important disadvantage of immuno-
suppressed mice is their tendency to recover the
ability to reject human tumour cells during the few
months following the procedure. Steel et al., (1978)
found evidence for this by 6 weeks and it was
subsequently found that raising the dose of whole-
body irradiation increased the length of time for
which the mice seemed highly receptive to about 3
months (Steel et al., 1980). Mice given radiation
doses of 10 or Gy are more fragile than those
given the standard dose and the oral administration
of neomycin was necessary to reduce mortality.
Further attempts to improve the receptivity of
mice to xenografts were reported by Bailey et al.,
(1980a). In an effort to improve the take-rate of
human breast tumours, which have widely been
found difficult to graft, a variety of modifications
were made to the immuno-suppression procedure.
The age of the recipients at thymectomy was
reduced from 4 to 3 weeks; the radiation dose was
raised to lOGy, silica particles were injected i.p.,
oestrogen was administered, castrated male mice
were used, the size of the tumour implant was
increased, and nude mice were also used (these
procedures were, of course, only tested singly).
None of the techniques appeared to be an
improvement over the standard procedure and the
overall success rate (8 lines established from 80
patients) remained comparable with results reported
by other investigators (Giovanella et al., 1976;
Sebesteny et al., 1979; Rae-Venter & Reid, 1980).
Success rate in establishing xenograft lines
During the course of the present programme a total
of 329 individual human tumours have been
investigated. Table 1 shows their breakdown by
tumour type. The main emphasis has been on colo-
rectal tumours (52% success rate), breast carcinomas
(10%), bronchial carcinomas (78%), testicular
teratomas (30%) and ovarian carcinomas (23%).
These success rates indicate the proportion of
clinical specimens that yielded serially
transplantable lines. It must be emphasised that
each of these tumour types was studied by a
different scientist and that, as indicated in the
previous section, the technique of immune
deprivation has varied over the 7-year period. It
would, however, seem clear that breast and ovarian
tumours (especially ascites) have generally been
more difficult to graft, with melanomas and
tumours of the colon and bronchus being relatively
successful.
Table I Summary of xenograft success rates
Number
of Number of Success
patients lines rate
Tumour location and type tested established (%) References
Colon-rectum ca. 65 34 52 Pickard et al., (1975);
Nowak et al., (1978)
Stomach ca. 0 I
Pancreas ca. 2 1 50
Glioma 5 0
Melanoma 15 9 60 Selby et al., (1980)
Breast ca. 80 8 10 Bailey et al., (1980a)
Bronchus: adenocarcinoma 6 6 100
squamous 17 11 65 Shorthouse (1980a,b)
small-cell 18 15 83
large-cell 8 6 75J
Testicular tumours: MTU 26 9 35
MTI 17 3 18
MTT 6 2 30 Gibbs et al., (unpublished),
seminoma 2 0 referred to in Raghavan et
al., ( 981)
mixed 8 3 38 J
Ovary ca.: solid 44 11 23 Selby et al., (1980); Jones
(unpublished)
ascites 9 0
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Maintenance of biological characteristics in
xenografts
Over the course of this series of projects a
considerable body of evidence has accumulated on
the extent to which xenografts maintain the
characteristics of the source tumours. A basic
requirement is the maintenance of a human
karyotype. This was studied in detail by Reeves &
Houghton on 2 colon carcinomas which formed
part of a related research project. Human
karyotypes were retained through serial passage
although there were progressive changes in the
distribution of chromosomes. An extra chromosome
19 appeared in one tumour and the progressive
selection of sidelines was noted. Human
chromosomes were also found in the 2 colonic and
bronchial xenografts studied by Kopper & Steel
(1975), in 10 melanomas studied by Selby et al.,
(1980), in 16 bronchial carcinomas studied by
Shorthouse et al., (1980), in 9 ovarian carcinomas
(Jones et al., 1982) and in 6 testicular teratomas
(Raghavan et al., 1981). These investigations (which
were performed by J. Mills and G. Casey) showed
the occasional occurrence of a mouse mitotic figure
which could arise from proliferating cells in the
mouse stroma. No hybrid karyotypes were ever
observed. There was, however, one case of a
rapidly-growing tumour with an exclusively mouse
karyotype appearing at the transplantation site of a
teratoma xenograft which originally contained
human chromosomes. Studies of LDH isoenzymes
(Houghton & Taylor, 1978a) similarly confirmed
the human origin of 6 colon carcinoma xenografts
and all of 7 ovarian carcinoma lines were positive
for human epithelial membrane antigen (Jones et
al., 1982).
Histological comparisons of the xenografts with
their source tumours have been made in each type
of tumour. In agreement with other investigators,
our experience has been that the histological
characteristics of the source tumours are usually
well maintained by xenografts. Often the stromal
elements are less pronounced and this may be
associated with the more rapid growth of the
tumours in the mouse than in man, and with the
fact that the stromal tissue is of mouse origin
(Warenius, 1980). There was a frequent, but not
universal tendency for the xenografts to be
more anaplastic and pleomorphic than the
source tumours. Houghton & Taylor (1978a) in
colonic carcinomas and Shorthouse (1981) in
bronchial carcinomas found that the pattern of
production of epithelial mucins was well
maintained. We have not observed the tendency
towards increased differentiation reported by
Sharkey et al., (1978).
Tests for the presence of marker substances have
been made in a number of disease categories.
Shorthouse et al., (1982) demonstrated positive
assays for ectopic hormones in bronchial
carcinomas: calcitonin (in 13% of xenografts),
PHCG (in 13%), ACTH (in 78%) and CEA (in 56%).
The synthesis (as opposed to presence) of calcitonin,
fHCG and ACTH was also demonstrated in
proliferative cultures of a few cell lines and in 2 of
these cases fHCG was also demonstrable in mouse
plasma. Marker production in teratoma xenografts
has been summarised by Raghaven et al., (1981).
Among 6 lines that were studied, 2 showed strong
production of alphafoetoprotein (AFP) and in both
cases the original patient specimen was also
strongly positive for AFP. Similarly, a negative
assay correlated with negative in the original
specimen. The production of CEA by colon
carcinoma xenografts was studied by Houghton
& Taylor (1978a). The protein was detected in all
tested specimens of xenografts and high levels were
associated with high levels in the clinical specimens.
When affinity-purified antibodies to CEA were
injected into mice bearing breast carcinoma
xenografts (3 of the lines indicated in Table I)
specific localisation in tumour tissue was observed
(Moshakis et al., 1981).
Growth rates
The growth rates of xenografts were determined by
caliper measurements on s.c. tumour implants. In
most cases these were transformed into tumour
volumes using the equation for the volume of an
ellipsoid but in the case of the teratomas a
calibration curve technique was used in which an
empirically-determined relationship between the
caliper measurements and the excised tumour
weight was used to interpret subsequent caliper
measurements (Steel, 1977, p.6).
A summary of growth rate data is given in Table
II. The measurements were usually made on
tumours in the size range 0.1-0.5g (about 8-13mm
diameter). Growth rate often decreased with
increasing tumour size, as is almost always found
with syngeneic or xenografted tumours in the
mouse (Steel, 1977). It can be seen that in passage 0
(man-mouse) the average volume-doubling times
range from 13.5 days in melanomas to 29.5 days in
breast carcinomas. This difference is just significant
at the 5% level. In the subsequent passages an
increase in growth rate was found in all the tumour
types, the overall average doubling time falling from
19.8 days to 11.1 days. Further acceleration
sometimes occurred beyond passage 4. The most
detailed study of growth acceleration through4 G.G. STEEL, V.D. COURTENAY & M.J. PECKHAM
Table II Volume-doubling times of xenografts
Passage 0* Passage 2-4*
Mean SD n Mean s.d. n References
Colon ca. 14.5 6.0 22 Kopper & Steel (1975);
Nowak et al., (1978)
Colon ca. 22.3 13.0 5 12.1 4.1 5 Houghton & Taylor (1978b)
Breast ca. 29.5 17.5 8 9.5 3.0 8 Bailey et al., (1980a)
Lung ca.:
Small-cell 21.2 14.8 13 14.0 10.4 7
Squamous 17.8 7.1 10 10.7 2 l Shorthouse et al., (1980a and b)
Adenocarcinoma 15.0 6.2 6 9.4 6.0 4 Shorthouse (1981)
Large-cell 14.4 15.0 6 2-J
Melanoma 13.5 9.2 7 12.0 8.0 8 Selby et al., (1980)
Ovarian ca. 21.5 13.0 12 Selby et al., (1980); Jones (unpub.)
Teratoma 8.1**
1.4 4 Gibbs et al., (unpub.)
Volume-doubling times in days.
*Passage 0 is the man-mouse passage;
Passage 1 is the first mouse-mouse passage etc.
**Passages 3-10.
sequential passage was the work of Houghton
& Taylor (1978b) who studied 6 colon
carcinomas through up to 10 passages in male and
female mice; the growth-rate changes were most
marked during the first 3 passages. It will be seen in
Table II that acceleration may not occur
proportionately in each tumour type. For instance
breast carcinomas, which grew the slowest in the
first passage, grew faster than other tumours in the
subsequent passages.
It is of some interest to ask whether there is a
correlation between the success rate of xenografts in
the first passage and their growth rate. Are we
selecting tumours that grow rapidly? A comparison
of the data in Tables I and II reveals no correlation
between the growth rate and success rate of these
major xenograft categories (Figure 1). The only
result that is suggestive of such a correlation is the
low success rate and slow growth of the breast
carcinomas. However, a positive correlation
between growth rate and take-rate among bronchial
carcinoma xenografts was found by Shorthouse
(1981). Selection in favour of rapidly growing cells is
suggested by the clear tendency of xenografts to
accelerate during passage in mice and by their
tendency towards higher growth rate than is found
in the patients. Clinical tumour growth rate data
are available on few of the patients who donated
tissues for the xenografts in this series (Shorthouse,
1981) but it is possible to compare the present data
with other published data on human tumour
growth rates (Steel, 1977; Table 1.2 and Figure
1.19). Lung metastases from carcinomas in various
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Figure 1 Lack ofcorrelation between success-rate and
growth rate. Success-rates (Table 1) indicate the
proportion of tested patients from whom
transplantable lines were obtained; growth rates (Table
2) are for passage 0 (man-mouse) of those lines that
grew.
primary sites have been found to have a wide range
of growth rates whose average is around 60-90
days (not significantly different among the primary
sites). It would therefore seem that on average the
xenografts that do grow in mice have, even in their
earliest passage, a higher growth rate than is found
in most human lung metastases. The difference
could be approximately a factor of 2 to 6.
The in situ response of xenografts to
chemotherapy
Much of the work in the present programme on the
response of xenografts to chemotherapeutic
uu
ICHEMOTHERAPY OF HUMAN TUMOUR XENOGRAFTS 5
treatment has employed tumour growth delay as
the end-point of effect. A group of immuno-
suppressed mice are implanted with tumours,
usually within a few days of the immuno-
suppressive radiation treatment. Not all implants
grow at the same rate or with the same latency
period. When a good number of them have grown
beyond about 7mm diameter the tumours are
accurately measured. Those falling within a defined
range of size (say 8-10mm average superficial
diameter) are selected and split into comparable
groups each containing, say, 6-10 tumours. One
group is kept as a control, the others are treated
with one or more drugs at one or more dose levels.
Caliper measurements are then continued
approximately 3 times per week and tumour
volumes are calculated either by a geometrical
formula or using a calibration curve technique.
In an idealised situation the results are as shown
in Figure 2. Growth of the treated tumours is
retarded and they may even temporarily regress.
The response curve for the treated tumours may be
divided into 2 components: a declining component
that represents the clearance of dead tissue and a
regrowth component that initially is hidden but
which eventually becomes dominant (see Steel, 1977,
p. 249). It is the second of these that reliably
indicates the effects of treatment. The usual
procedure, therefore is to choose a tumour volume
that is a simple multiple of the tumour size at
treatment and to measure the time taken for the
treated and control tumours to reach this size. The
greater the multiple, the more confident one can be
that the treated tumours are actively regrowing
beyond the treatment size.
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Figure 2 Diagram of tumour volume response to
treatment, indicating the measurement of tumour
growth delay and fractional volume reduction (FVR).
If, for simplicity, the end-point is taken at a
relative volume of twice the treatment size then we
can determine the time taken (T2, TI) for control
and treated tumours to double their volume. The
difference (T' - T2) equals the actual tumour
growth delay.
If it is necessary to compare growth delay values
between tumour types that differ widely in growth
rate, the actual growth delay is clearly
unsatisfactory. We have therefore followed the
practice ofcalculating
T'-T2 Specific Growth Delay= 2 2
T2
This could be described as the number of
volume-doubling times by which growth is delayed
and it allows comparisons to be made between
tumours of different growth rate. Nevertheless, we
recognise that even this manoeuvre is not ideal.
There is good evidence (Stephens & Peacock, 1977;
Steel & Stephens, 1978) that the tumour cells which
survive cytotoxic treatment can repopulate with a
doubling time that is considerably shorter than the
doubling time of tumours at the time of treatment.
This work also shows from one cytotoxic drug to
another the rate of repopulation may differ. To
interpret or to compare growth delay values one
would like to divide them by the average doubling
time of surviving clonogenic cells during the
regrowth period up to TI but of course this is not
known. The specific growth delay values as
calculated must be regarded as the best
approximation available to a standardised growth
delay estimate.
The choice of drug dose is another difficult
problem in xenograft chemotherapy studies,
especially where the intention is to compare the
effectiveness of a series of drugs. The procedure
used throughout the present group of studies has
been to employ each drug at its maximum tolerated
dose in mice. The rationale behind this lies in the
claim by Freireich et al., (1966) that a linear
relationship exists between the LD1o doses of
cytotoxic drugs in mice and their maximum-
tolerated levels in man. The necessary comparative
pharmacokinetic data between man and mouse that
might allow a more reliable choice of doses are not
available.
Figure 3 is a summary of growth delay data on 6
types of human cancer grown as xenografts. In each
case the specific growth delay at an LD10 drug dose
has been calculated. The actual drug doses used
varied slightly from one study to another and the
teratomas and small-cell lung tumours were so
sensitive to treatment that in these cases to avoid
cures it was necessary to stay well below the LD1o
level. The growth delay values have therefore been
l6 G.G. STEEL, V.D. COURTENAY & M.J. PECKHAM
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Figure 3 Summary of xenograft response to chemotherapy. The ordinate in each panel indicates the specific
growth delay (volume doubling times saved by LD10 single drug dose). Each point indicates a separate
xenograft line; upward arrow indicates more than half the grafts failed to regrow. The histograms show the
mean growth delay for each group of lines, and is not calculated when the spread of values is clearly not
Gaussian. Drug abbreviations given in Table III. Drug combinations are: CMF(CY+MTX +FU);
AV(Adr+VCR); MCC(MTX +CY+CNU); VAP(VCR+Adr+Pro); CAF(CY+Adr+FU).
adjusted to the LD1o dose by linear extrapolation
or interpolation and the LD1o values used for this
are given in Table 3. The choice of drugs used
against each tumour was influenced by their known
clinical activity or potential interest. The panels of
data in Figure 3 are arranged in order of decreasing
tumour response. Colo-rectal carcinomas, non-
small-cell lung tumours and melanomas did not
significantly exceed an average specific growth delay
of 1.0 with any drug. Breast carcinomas responded
well to 4 of the single agents as well as to the 2
drug combinations. Small-cell lung tumours were
cured by large doses of cyclophosphamide,
procarbazine, or the MCC combination
(methotrexate, cyclophosphamide, CCNU). The
testicular tumours were similarly very responsive:
the growth delay values given have in most cases
been extrapolated from results actually obtained
with doses around one-fifth of the LD10 level.
It is apparent that these data broadly reflect
clinical experience with chemotherapy in these
disease areas. The implications of this will be
considered in more detail under General
conclusions.
Volume reduction as an alternative in situ end-
point
A serious potential problem in xenograft growth
delay experiments arises from the fact that the
greater the magnitude of the therapeutic response
the longer host defence mechanisms have to act. In
so far as the host is capable of being immunised
and of mounting an immunological attack on the
tumour, this could lead to a systematic
enhancement of tumour response which may be
dose-dependent. The participation of host immune
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Table III Assumed LD10 dose levels
Drug Abbreviation LD10 (mgkg 1)
Cyclophosphamide CY 250
Melphalan Mel 15
cis-Platinum Pt 10
CBDCA CB 160
Hexamethylmelamine HMM 350
CCNU CNU 50
MeCCNU MNU 35
Procarbazine Pro 1500*
Bleomycin Ble 300
Adriamycin Adr 12
Actinomycin D AD 0.5
5-Fluorouracil FU 185
Methotrexate MTX 100*
Vinblastine VLB 2
Vincristine VCR 1.8*
DTIC 200
VP16 VP 40*
Mitomycin C MC 6.5
Streptozotocin SZ 250
*All drugs given as a single i.p. dose, except MTX
which was usually given in 3 doses over 24h, procarbazine
given in 5 daily doses, vincristine on days 1 and 5, and
VP16 in 3 daily doses.
response in enhancing tumour cure has been well
demonstrated in the non-xenograft situation
(Mantovani et al., 1979; Hengst et al., 1981). In a
number of chemotherapy studies on xenografts
tumour cure was observed at drug doses that on
the basis of lower dose studies would not have been
expected to produce a very long growth delay. For
instance, Kopper & Steel (1975) using a small-cell
bronchial carcinoma in marrow-reconstituted mice
found that cyclophosphamide gave a growth delay
of 1.1 volume-doubling times at a dose of
120mgkg-1 and 3/8 tumours failed to regrow after
a dose of 180mgkg-'. Such evidence suggests that
clonogenic cell kill of only perhaps 2 decades (a
surviving fraction of 1%) may achieve substantial
tumour control when combined with an effective
immune response. Whether this also leads to
upward-bending dose-response curves at
noncurative doses is not yet clear, for a survey of
the literature reveals few well-defined dose-response
curves for xenografts. Two studies from the present
programme have examined tumour growth delay as
a function of dose and in both cases the dose-
response curves were almost linear: small-cell lung
tumours studied by Shorthouse et al., (1982) and
breast carcinoma xenografts studied by Bailey
et al., (1980b). However, a survey of published dose-
response data for the radiation treatment of
xenografts shows that there has been a tendency
towards upward curvature (see e.g. Rofstad &
Brustad, (1978, 1980), who used melanomas and
osteosarcomas in nude mice).
In face of the evident possibility of artefacts
resulting from this phenomenon, we have also
explored the use of a tumour growth inhibition end-
point: at some fixed time after treatment to measure
the relative volume of treated and control tumours.
This procedure has been widely used in
experimental chemotherapy, including some studies
on xenografts (Povlsen & Jacobsen, 1975;
Shimosato et al., 1977). The method has been
criticised on the grounds that if the size
determinations are made too early tumour
regression will not yet be complete and the
magnitude of response will be underestimated. But
the method could be reliable provided there is
evidence that at the time of measurement the
treated tumours are actively regrowing. We have
therefore re-analysed our data using this restriction,
evaluating for each treated and control tumour the
relative tumour size (V) at the end of the growth
period compared with their size at the time of
treatment and then calculating
Fractional Volume Reduction (FVR)
mean Vc =1o0 mean Vt
(see Figure 2).
This gives the number of decades by which the
treated tumour volume is reduced below the control
value. FVR= 1.0 indicates treated tumours 1/10 of
control; FVR=2.0 indicates treated tumours 1/100
of control.
Results on a range of different xenograft types are
shown in Figure 4 as a comparison with the
corresponding growth delay value. For breast,
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Figure 4 Correlation between FVR and growth delay.
O Small-cell ca.; V Non-small-cell ca. bronchus; 0
Breast ca.; A Colo-rectal ca.; 0 Testicular teratoma.
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colon and lung tumours (small-cell and non-small-
cell tumours) the data seem to fall around a
common line; for testicular teratomas the data give
a steeper slope. This could be due to the rapid
regression of the teratomas making it easier to
obtain an FVR determination that truly reflects the
reduction in the volume of viable tissue. The slope
of the curve for teratomas is about 0.3, close to
log,02 and this is consistent with the expectation
that a delay of one volume-doubling time results in
treated tumours that are half the size of controls.
The FVR method is now in use for therapeutic
studies on xenografts, for instance in teratomas
which tend, especially after treatment, to become
cystic. The opportunity to excise the tumours at
one particular time and determine the cellular
composition by weighing is an associated advantage
over the growth delay method.
Comparative cell survival studies among xenografts
The principal alternative to in situ methods of
measuring therapeutic response in xenografts is to
determine clonogenic cell survival. Tumour-bearing
mice are treated, the tumours are excised within
about a day, disaggregated into a single-cell
suspension and the cells placed in an in vitro
(or perhaps in vivo) environment in which their
ability to form a colony can be evaluated (for
review see Elkind & Whitmore, 1967; Steel, 1977). A
number of clonogenic assays have been developed
for xenografted human tumours (Courtenay & Mills,
1978; Smith et al., 1976; Selby et al., 1980; Selby &
Steel, 1982). Plating efficiencies vary widely from
very low levels in some tumours to - 30% in
favourable cases. Problems of tissue disaggregation
are sometimes severe and at the present time only a
minority of xenografted tumours are amenable to
reliable clonogenic assay.
The great advantage of clonogenic cell survival as
an end-point for xenograft studies is that by
removing the treated and control cells into a
common environment problems of host defence
mechanisms are avoided. Other advantages of this
approach are its sensitivity (often down to a
surviving fraction of 10-3) and its ability to detect
the presence or absence of resistant components
within the tumour or a "shoulder" at low drug
doses.
Chemotherapy studies of cell survival in the
present research programme have included studies
on pancreatic and bronchial carcinomas,
melanomas, and a single survival curve for a colon
carcinoma. Survival curves were in almost all cases
indistinguishable from an exponential, with rare
examples of a small shoulder. The only marked
exception to this was in the response of two of the
melanomas to DTIC, where the curves fell to a
clear plateau at about 10-2 survival for drug doses
in excess of 100mgkg-'. The steepness of the
survival curves can therefore in most cases be
expressed by the surviving fraction at the LD1o
dose and these values (given as decades of cell kill)
are summarised in Table IV. Values in excess of 3.0
indicate situations in which the survival at the
LD1o dose was too low to measure, and linear
extrapolation has been used.
Although data in Table IV do not include a wide
variety of drugs or an extensive range of tumour
types they do support the implications of the
growth delay data that among a group of similar
tumours the effectiveness of a particular drug can
vary widely. It is even possible in some cases to
quantify the variation: among the melanomas there
is a 3-fold range of sensitivity to melphalan and a
>5-fold range for MeCCNU. The two pancreatic
tumour lines have very similar sensitivities to most
drugs used but a >5-fold difference for
hexamethylmelamine (Courtenay et al., 1982). There
is little opportunity to ask whether the cloning data
also support the large differences between sensitive
and resistant tumour types seen in Figure 3, for
only 2 data points are available for nominally
chemosensitive disease: the small-cell carcinomas
treated with the 3-drug combination MCC. These
two were, however, very responsive.
Relation between cell survival and tumour growth
delay
It is of some interest to enquire to what extent
measurements of clonogenic cell survival correlate
with growth delay measurements on the same drugs
and tumours. The number of tumours in which this
comparison can be made is not large and the data
are summarised in Figure 5. For points below a
surviving fraction of 10-3 the survivals have been
obtained by extrapolation up to the dose used in
the growth delay determinations.
Among the sensitive tumours (i.e. those that give
a specific growth delay greater than 1.0 or a
surviving fraction below say 0.3) there is a general
tendency for growth delay and log cell kill to
increase together. There is by no means a tight
relationship between these parameters, nor would
one expect this. As shown in the B16 mouse
melanoma by Stephens & Peacock (1977) the
growth delay achieved for a fixed level of cell kill
depends upon the drug used: for cyclophosphamide
the growth delay was considerably greater than for
CCNU and this difference was attributed to a faster
rate of repopulation by surviving clonogenic cells
after CCNU.CHEMOTHERAPY OF HUMAN TUMOUR XENOGRAFTS
Table IV Cell survival following in vivo treatment (Decades ofcell kill at LD10 dose)*
PE** CY Mel MNU Adr DTIC HMM Pt FU MC SZ MCCI
Pancreatic ca.:
HX32 25-30 0.4 3.0 1.0 2.3 0.7 3.5 0
HX58 7-18 1.0 3.0 1.0 0.2 0.7 0
Melanomas:
HX34 10-50 0.4 2.2 7 0.1 2.6t 1.5 0.9 0.9 2.3
HX40 2-13 2.1 3.0 0.1
HX41 10-75 0.3 0.9 0.3 0 0.1
HX46 2-6 3.0 2.0 0.1
HX47 3-18 2.0 4.5 0 2.2t
Colon ca.:
HX18 1.0 0.6
Small-cell lung tumours:
HX72 3 4.3
HX81 3-6 21
Lung Adenocarcinoma:
HX70 2-5 0.7 0.5 0.5
*Values in excess of 3.0 were obtained by extrapolation. Results on melanomas mostly determined by the
agar diffusion chamber assay (Selby et al., 1980); the rest by in vitro assay (Courtenay & Mills, 1978).
**Plating Efficiency (%/6). Abbreviations for drugs are given in Table III, together with assumed LD10 values.
tNon-exponential survival curves.
tMCC =methotrexate+CY+CCNU.
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The data presented in Figure 3 and Table IV clearly
show that xenografts generally maintain the
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question is what variations in chemosensitivity
exist among a group of xenografts of the same class.
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drugs. Even drugs such as methotrexate and
actinomycin D, which ranked poorest overall,
achieved good responses (2.7 and 2.9 in one
tumour line.
2. Bailey et al. (1980b). This was a similar study
in breast carcinoma xenografts, employing
5 tumour lines challenged with 6 single agents
and two drug combinations. By comparison with
the colo-rectal tumours, this disease was more
responsive to chemotherapy with an overall
mean specific growth delay of 2.0. In this case
there were significant differences among the
tumour lines in their response to chemotherapy
as well as significant differences among drugs in
their effectiveness. Superimposed on these
differences was an apparent degree of
individuality in response to the most effective
drugs: of the 5 tumour lines, one responded best
to the CMF combination, 2 were best with
melphalan and 2 best with the AV combination
(see Legend to Figure 3).
3. Shorthouse et al., (1980ab; 1982). In this
extensive study on xenografts of bronchial
carcinomas there was evidence that in addition
to the marked differences between small-cell and
non-small-cell tumours, those within a particular
histopathological type also differed in drug
sensitivity. There was no evidence for a
difference in spectrum of drug response but some
tumours were markedly more responsive than
others.
4. Selby et al., (1980). In this cell survival study on
5 melanoma xenograft lines measurable
responses were only available to 3 drugs
(melphalan, MeCCNU and DTIC). There was no
evidence for individuality among these tumours
and drugs. However, a parallel programme of in
vitro chemosensitivity testing was carried out by
Bateman et al., (1980) and a statistical analysis of
the data yielded evidence for significant
individuality in the response of 5 melanoma
xenografts to melphalan, MeCCNU, cis-platinum
and adriamycin.
5. Courtenay et al., (1982). Two pancreatic
carcinoma xenografts were evaluated in response
to 6 cytotoxic drugs by clonogenic cell survival.
Their response to 4 agents (melphalan,
MeCCNU, cis-platinum and streptozotocin) was
indistinguishable. There was a slight difference in
response to cyclophosphamide but a large
difference in response to hexamethylmelamine.
These studies comprise a body of data that
broadly supports the individuality hypothesis. In
the case of the growth delay data the evidence
would have been stronger if it had been possible to
perform a series of repeat experiments with each
tumour-drug combination. But in the case of the
cell survival studies (especially no. 5 above) where
repeat experiments were performed the difference in
spectrum of drug response among the tumours was
highly significant.
Comparison of xenograft with donor patient response
The most precise and relevant way of validating the
xenograft system for therapeutic purposes is directly
to compare xenograft response with the clinical
response of the donor patient. This is logistically a
difficult type of investigation because of the
combined effect of unavoidable factors: the
proportion of donor patients who receive
chemotherapy may be small; few of them may give
an objectively measurable clinical response; the
xenograft success rate may be <50%. In spite of
these limitations, comparisons of this type have
been possible in 3 disease areas:
1. Colo-rectal Cancer. Four of the patients studied
by Nowak et al., (1978) received chemotherapy
(MeCCNU, 5FU and DTIC). In three there was
no evidence of a therapeutic response and the
disease progressed. One achieved an objective
clinical response, and the xenografts from this
patient were the most responsive (of the 10
xenograft lines studied) to MeCCNU and also
responsive to 5FU.
2. Melanoma. Two of the donor patients in the
melanoma study of Selby et al., (1980) had
measurable lung metastases and were treated
with melphalan. One (donor of HX47) showed
an objective response but the other (HX41) did
not. The melphalan cell survival curve for the
xenografts was twice as steep in HX47 as in
HX41.
3. Bronchial Carcinoma. The major study of this
type was that of Shorthouse et al., (1980ab).
Xenograft and donor patient response was
evaluated in 7 small-cell carcinomas, 3 squamous
carcinomas, 4 adenocarcinomas and one large-
cell carcinoma. The clinical response of small-cell
tumours was reflected in highly responsive
xenografts, as was the lack of response of the
non-small-cell tumours. Two previously-treated
patients with small-cell cancer failed to achieve a
clinical response, and the xenografts were
similarly resistant.
The consistency of agreement between patient
and xenograft responses in these studies is
encouraging. This does not of course mean that
there is a realistic prospect of using xenografts for
clinical chemosensitivity testing, since as discussed
by Bailey et al., (1981) the limitations of speed of
assay and of success rate would limit the
proportion of patients helped to only 10-20%.CHEMOTHERAPY OF HUMAN TUMOUR XENOGRAFTS 11
However, the use of xenografts as models of
particular human cancers is supported.
General conclusions
The body of data reviewed here comes from work
on a wide range of types of human cancer, not only
in respect of tissue origin but also of responsiveness
to cytotoxic drug treatment. The drawbacks of in
situ growth delay or cell survival studies have been
indicated, but in spite of these there is clear
evidence that the xenografts respond to drug
treatment in a way that broadly would be expected
on the basis of clinical experience. In terms of
average response to the 3 agents that in each case
were most effective, the 6 categories of disease for
which results are shown in Figure 3 can be ranked
(Table V). This ranking is compared in Table V with
estimates of complete response rate achieved in
current clinical practice. Response rates vary
considerably from one report to another, but we
have included in Table V average values from recent
review papers or, where these are unavailable,
typical values from recent large series. Although the
drugs and drug schedules used in these clinical
studies were not the same as those used to calculate
the xenograft average values, the correspondence
between the xenograft and clinical response data is
remarkable.
In addition to this plausible inter-type ranking
there is also evidence that in any particular tumour
type the drugs that do well clinically also rank high
in xenografts: cyclophosphamide, CCNU and
vincristine in small-cell lung cancer; bleomycin, and
cis-platinum in testicular teratoma. However, there
are also some surprising results, notably the marked
effectiveness of procarbazine in small-cell tumours
and the relatively poor performance of adriamycin
in other than breast tumours. The ineffectiveness of
VP16 in teratomas may well be associated with the
known difficulty of ensuring high enough
concentrations of this agent in a soluble form in
mice; we suspect that as a result of this drug
delivery problem the present data may under-rate the
value of this agent. The relatively poor performance
of methotrexate in breast and small-cell tumours is
also remarkable, especially in view of the higher
growth rate of the xenografts than of the
corresponding disease in man. The breast xenografts
received single dose treatment, the small-cell
xenografts 3 doses over 24h. We are inclined to
accept the xenograft data on methotrexate as
possible evidence that the clinical activity of this
drug may have been over-rated.
A number of combination chemotherapy
schedules have been evaluated in the present work
(Kopper & Steel, 1975; Nowak et al., 1978; Bailey
et al., 1980b; Shorthouse et al., 1982). There has
not been space in this publication to review these
studies in detail. However, they can be summarised
in the statement that in no case was there
statistically significant evidence for the growth delay
of a drug combination exceeding the aggregate
growth delays of the component single agents.
Combination chemotherapy was usually effective in
that a greater tumour response could be achieved
within the toxicity limitations of the host than with
any single agent, but this is to be attributed to non-
overlapping toxicity rather than to "synergistic"
effects against tumour cells.
The assessment of therapeutic response in human
tumour xenografts is not a simple matter. In situ
measurements of response are vulnerable to
artefacts from the substantial host response that
appears to be mounted against grafts in immuno-
suppressed mice. This problem is not restricted to
artificially immuno-suppressed mice for there is also
evidence for such responses in nude mice (Sordat et
al., 1982). Further studies are under way in which
Table V Comparative responsiveness to chemotherapy in six categories of human tumour xenograft
and their clinical counterparts
Average xenograft Clinical complete
growth delay* response rate (%) Source ofclinical data**
Testicular teratoma 5.7 70 Einhorn (1979)
Small-cell lung cancer 4.2 31 Minna et al., (1982)
Breast cancer 1.9 15.3 Hellman et al., (1982)
Melanoma 1.0 4 Wittes et al., (1978)
Colo-rectal cancer 0.76 3 Kemeny et al., (1980)
Non-small-cell lung cancer 0.54 5 Minna et al., (1982)
*Average number of volume-doubling times saved by maximum tolerated dose treatment using the 3
single agents in common clinical use that were most effective in each category; data from Figure 3.
**These comprise review papers or individual publications that reflect general clinical experience.12 G.G. STEEL, V.D. COURTENAY & M.J. PECKHAM
this is being investigated, especially in response to
local irradiation of the grafts. Clonogenic assays
obviate the host response problem but as yet their
application to a wide range of xenograft types has
been limited by problems of tissue disaggregation
and cell cloning. The main benefit of the clonogenic
assay work has been in the study ofthe shape ofcell
survival curves. Drugs were chosen that gave a
good response or were of clinical interest for the
disease in question. For almost all of these
cytotoxic agents the curves have been exponential,
implying that the cellular sensitivity was relatively
homogeneous within the tumours.
In view of the greater cost and technical
limitations a programme on this scale could not
have been mounted in nude mice and we are
encouraged, in spite of the lack of stability of
immune response in immuno-suppressed mice, to
continue using them in studies of this type.
As well as acknowledging the participation of the clinical
scientists listed above, we are grateful to John Gibbs,
Judith Mills and Patricia Wilson for technical support, to
Ted Merryweather for care of the animals, and to Louise
Parkes for typing the manuscript.
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